These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24313118)

  • 21. Treatment of infants coinfected with HIV-1 and cytomegalovirus with combination antiretrovirals and ganciclovir.
    Saitoh A; Viani RM; Schrier RD; Spector SA
    J Allergy Clin Immunol; 2004 Oct; 114(4):983-5. PubMed ID: 15480350
    [No Abstract]   [Full Text] [Related]  

  • 22. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.
    Nischalke HD; Vogel M; Mauss S; Baumgarten A; Lutz T; Danta M; Naumann U; Coenen M; Sauerbruch T; Rockstroh JK; Spengler U; Nattermann J
    AIDS; 2010 Aug; 24(13):2001-7. PubMed ID: 20588168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment for hepatitis C in patients infected with human immunodeficiency virus.
    Fernández I; Muñoz R; Solís-Herruzo JA
    Rev Esp Enferm Dig; 2003 Apr; 95(4):287-91, 282-6. PubMed ID: 12826005
    [No Abstract]   [Full Text] [Related]  

  • 25. [The hepatitis C virus: after the track of the human immunodeficiency virus].
    Pérez-Olmeda M; Rodríguez-Rosado R; García-Samaniego J; Soriano V
    Rev Clin Esp; 1999 Jan; 199(1):5-7. PubMed ID: 10089769
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
    Nilsson J; Weiland O
    Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 29. Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells.
    Page EE; Cox A; Atkins M; Nelson MR
    AIDS; 2010 Jun; 24(9):1267-71. PubMed ID: 20386424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
    García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
    Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 33. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
    Boutolleau D; Canestri A; Burrel S; Wirden M; Seang S; Clavel-Osorio C; Marcelin AG; Katlama C; Agut H
    J Clin Virol; 2012 Jun; 54(2):194-6. PubMed ID: 22398036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus resistance testing: pitfalls and problems for the clinician.
    Drew WL
    Clin Infect Dis; 2010 Mar; 50(5):733-6. PubMed ID: 20100090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients.
    Berenguer J; Fernandez-Rodríguez A; Jimenez-Sousa MA; Cosín J; Zarate P; Micheloud D; López JC; Miralles P; Catalán P; Resino S
    Cytokine; 2012 Jan; 57(1):25-9. PubMed ID: 22136974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focus on hepatitis. Final APRICOT, ACTG A5071 results.
    Highleyman L
    IAPAC Mon; 2004 Sep; 10(9):356-7. PubMed ID: 15801102
    [No Abstract]   [Full Text] [Related]  

  • 39. HCV/HIV co-infection therapy.
    Pietrandoni G
    Posit Aware; 2002; 13(2):32, 38. PubMed ID: 12004829
    [No Abstract]   [Full Text] [Related]  

  • 40. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence.
    Taylor LE; Schwartzapfel B; Allen S; Jacobs G; Mitty J
    Clin Infect Dis; 2003 Jun; 36(11):1501-2; author reply 1502-3. PubMed ID: 12766851
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.